Skip to main content
. 2018 Nov 5;9:2552. doi: 10.3389/fimmu.2018.02552

Figure 3.

Figure 3

CD16.NK-92 has natural preference to kill CD45RA– CD4+ memory T cells and that is enhanced by alefacept in healthy donors. (A) Representative healthy donor flow cytometry plots from killing assay with CD16.NK-92 and healthy donor CD4+ T cells 19 h in co-culture with CD45RA subsetting shown with no treatment, with CD16.NK-92 and 10 μg/mL alefacept or IgG1 control antibody. (B) CD2 MFI of CD16.NK-92, and CD4+ T cells. (C) Percent cytotoxicity of CD4+ T cells in killing assay with CD16.NK-92 after 19 h in co-culture with 10 μg/mL alefacept or IgG1 control antibody and E:T ratio dose response, as measured by absolute count flow cytometry. (D) Percent cytotoxicity of CD16.NK-92 in killing assay 19 h in co-culture with 10 μg/mL alefacept or IgG1 control antibody and E:T ratio dose response, as measured by absolute count flow cytometry. (E) Percent cytotoxicity of CD45RA+ and CD45RA– subsets of CD4+ T cells (as shown in C) at E:T = 0.5:1 after 19 h co-culture with CD16.NK-92 and 10 μg/mL alefacept or IgG1 control antibody, as measured by absolute count flow cytometry. Mean and SEM shown for 6 healthy donors, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Statistical significance between IgG1 and alefacept conditions are indicated with black bars, statistical significance between cell types with IgG1 are indicated with gray bars and statistical significance between cell types with alefacept are indicated with red bars.